In a nutshell This study investigated the effectiveness and safety of brentuximab vedotin (Adcetris) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that brentuximab vedotin was effective and well-tolerated in these high-risk patients. Some background The...
Read More
In a nutshell This study evaluated the effectiveness and safety of the R-CyBorD (rituximab, cyclophosphamide, bortezomib, dexamethasone) regimen in patients with relapsed indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated in these patients. Some background There are many...
Read More
In a nutshell This article reviewed the use of proton therapy in adult patients with lymphoma in the mediastinum (the middle section of the chest around the lungs). Some background Many lymphomas are found in the mediastinum, next to the heart, lungs, and breasts. These organs are especially sensitive to chemotherapy and radiation therapy. In adult...
Read More
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read More
In a nutshell This study is investigating the effectiveness of ibrutinib (Imbruvica) for patients with relapsed or refractory (not responding to treatment) classical Hodgkin’s lymphoma (HL). Effectiveness is measured by the overall response rate (percentage of patients whose cancer shrinks or completely disappears after treatment). This study is...
Read MoreIn a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...
Read More
In a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...
Read More
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read MoreIn a nutshell This article reviewed the outcomes and side effects associated with maintenance therapies for diffuse large B-cell lymphoma and mantle cell lymphoma. Some background After initial treatment, patients with diffuse large B-cell lymphoma (DLBCL) may have disease progression within 1 to 2 years. Patients with mantle cell lymphoma (MCL) may...
Read MoreIn a nutshell This article reviewed the treatment options for patients with very high-risk diffuse large B-cell lymphoma (DLBCL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. DLBCL patients with certain risk factors may develop relapsed disease in the brain. The...
Read More
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read More
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read More
